Details of the Drug Reposition

General Information of This Drug (ID: DMKW0U6)

Drug Name
GT0918   DMKW0U6
Synonyms
KCBJGVDOSBKVKP-UHFFFAOYSA-N; UNII-QX6O64GP40; QX6O64GP40; 1398046-21-3; GT-0918; SCHEMBL12494226; 4-(4,4-Dimethyl-3-(6-(3-(2-oxazolyl)propyl)-3-pyridinyl)-5-oxo-2-thioxo-1-imidazolidinyl)-3-fluoro-2-(trifluoromethyl)-benzonitrile
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Prostate cancer DISF190Y 2C82.0 Phase 1/2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04728802) Proxalutamide Treatment for Hospitalized COVID-19 Patients. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)